Atea Pharmaceuticals (AVIR) shareholder Radoff-JEC Group said in an open letter Wednesday that it plans to nominate three directors at the company's annual general meeting as it raised concerns about Atea's stock price performance, strategy and governance practices.
Atea shares have traded below their net cash value since November 2021, according to the group, which said it owns about 5.4% of the company's outstanding stock.
The group said in the letter that it has made suggestions to improve the governance and management of the business, and the board has "ignored or rejected" its ideas.
There is an "urgent need for boardroom change," the investor group said, adding that with a refreshed board focused on creating stockholder value Atea could "immediately return up to $250 million in cash to stockholders."
In a statement Friday, Atea said its nominating and corporate governance committee would evaluate the director candidates "consistent with its established practices."
Atea's 2025 annual meeting has not yet been scheduled, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.